Trial Summary
What is the purpose of this trial?
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Research Team
LM
Linzee Mabrey, MD, MsC
Principal Investigator
Unversity of Washington
Eligibility Criteria
This trial is for hospitalized patients with ARDS, a severe lung condition often caused by infection or injury. Participants must meet specific health criteria to be eligible.Inclusion Criteria
P:F ratio < 300
I have a condition like pneumonia or major trauma that increases my risk for ARDS.
My breathing issues are not due to heart problems or fluid in my body.
See 5 more
Exclusion Criteria
I am only receiving treatment to ease symptoms.
Pregnant
Prisoners
See 7 more
Treatment Details
Interventions
- Atibuclimab (Monoclonal Antibodies)
Trial OverviewThe study tests IC14, an antibody treatment against CD14 in the blood, versus a placebo. Patients are randomly assigned to one of these treatments and monitored for oxygen levels over 28 days.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: IC14 (atibuclimab)Experimental Treatment1 Intervention
IC14 (atibuclimab) is a recombinant monoclonal antibody against human CD14
Group II: Identical-appearing placeboPlacebo Group1 Intervention
Sterile normal saline
Find a Clinic Near You
Who Is Running the Clinical Trial?
Implicit Bioscience
Lead Sponsor
Trials
12
Recruited
140+
University of Washington
Collaborator
Trials
1,858
Recruited
2,023,000+
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA